Live data · NADAC + Part D CY24 · reviewed daily

Dasatinib (PHYRAGO)

First FDA approval2006-06-27
Generic availableYes · 8 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$850.6M in CY2024 Part D spend75K claims · 16K beneficiaries · 329 plans surveyed

Lowest NADAC
$26.46/unit
10 NDCs benchmarked, lowest of all strengths.
Average NADAC
$82.93
Across all dosage forms in distribution.
Highest NADAC
$591.18
Wide spread — brand-strength NDCs still in market.
Plans with PA
1992 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Dasatinib used for?

Dasatinib is tracked in Medicare Part D. Specific indication information is not available in our current dataset.

Is there a generic for Dasatinib?

Yes. 48 ANDAs filed at FDA, 8 generic manufacturers currently shipping.

How much does my plan pay for Dasatinib?

Across 329 Part D plans, Dasatinib averages $82.93/unit (NADAC). Lowest available: $26.46/unit. Highest in distribution: $591.18/unit.

Is Dasatinib on the FDA shortage list?

No. Dasatinib is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh15 Oct 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (10 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.